Effects of Onabotulinum Toxin A on Gait in Parkinson's Disease Patients with Foot Dystonia.
Pei HuangYuan-Yuan LiJung E ParkPing HuangQin XiaoYing WangSheng ChenSheng-Di ChenJun LiuYi-Wen WuPublished in: The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques (2021)
We investigated the effects of botulinum toxin on gait in Parkinson's disease (PD) patients with foot dystonia. Six patients underwent onabotulinum toxin A injection and were assessed by Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS), visual analog scale (VAS) of pain, Timed Up and Go (TUG), Berg Balance Test (BBT), and 3D gait analysis at baseline, 1 month, and 3 months. BFMDRS (p = 0.002), VAS (p = 0.024), TUG (p = 0.028), and BBT (p = 0.034) were improved. Foot pressures at Toe 1 (p = 0.028) and Midfoot (p = 0.018) were reduced, indicating botulinum toxin's effects in alleviating the dystonia severity and pain and improving foot pressures during walking in PD.
Keyphrases
- botulinum toxin
- deep brain stimulation
- early onset
- chronic pain
- escherichia coli
- end stage renal disease
- pain management
- neuropathic pain
- cerebral palsy
- newly diagnosed
- chronic kidney disease
- ejection fraction
- peritoneal dialysis
- prognostic factors
- spinal cord injury
- lower limb
- ultrasound guided
- high resolution
- postoperative pain